ReviewCurrent research in pharmacology and drug discovery2021
Tuberculosis: Past, present and future of the treatment and drug discovery research.
Review in Current research in pharmacology and drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 57 citations in OpenAlex.
- Repurposing approved drugs as potential inhibitors of Mycobacterium tuberculosis ClpP: Structure-based virtual screening, molecular dynamics, and in vitro evaluation.Molecular diversity · 2026Article
- The Cyclic Di-GMP Receptor HpoR Modulates Mycobacterial Multidrug Susceptibility by Regulating IniBAC-Mediated Envelope Permeability.Microorganisms · 2026Article
- Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection AgainstVaccines · 2026Article
- Exploring the Natural Products Atlas (NPAtlas) Database for Hunting Prospective Irreversible Covalent DprE1 Inhibitors With Antitubercular Activity: An IntegratedJournal of tropical medicine · 2026Article
- Design, Synthesis,ACS omega · 2025Article
- Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.Natural products and bioprospecting · 2025Review
- Pharmacokinetic assessment and level-A IVIVC establishment of rifampicin-loaded 3D printed tablets using SLS 3D printing.Therapeutic delivery · 2025Article
- A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management.Journal of multidisciplinary healthcare · 2025Review
- Vγ9Vδ2 T cells expanded with vitamin C combined with HMBPPFrontiers in cellular and infection microbiology · 2025Article
- [Tuberculosis: Analysis of the history and development of multiple antibiotic resistance].Revista medica del Instituto Mexicano del Seguro Social · 2024Review
- Synthesis and Characterization of New N-acyl Hydrazone Derivatives of Carprofen as Potential Tuberculostatic Agents.Antibiotics (Basel, Switzerland) · 2024Article
- Review
- Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria.Frontiers in immunology · 2024Article
- Article
- Pathogenicity and virulence ofVirulence · 2023Review
- [Extensively drug-resistant tuberculosis treated with bedaquiline].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Machine Learning Prediction of Mycobacterial Cell Wall Permeability of Drugs and Drug-like Compounds.Molecules (Basel, Switzerland) · 2023Article
- Nanotherapeutic delivery of antibiotic cocktail enhances intra-macrophage killing ofFrontiers in antibiotics · 2023Article
- An In-Silico Evaluation of Anthraquinones as Potential Inhibitors of DNA Gyrase B ofMicroorganisms · 2022Article
- Determinants of Response at 2 Months of Treatment in a Cohort of Pakistani Patients with Pulmonary Tuberculosis.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is an infectious disease caused by the bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.